Back to Results

Synta 9090-11


Breast Cancer - Ganetespib Monotherapy In Women With Previously Untreated Breast Cancer

Therapeutic Area Breast Cancer
Principal Investigator John K. Erban, MD
Min Age 18 Years
Gender Female
Contact Jennifer Caplain
More Information


The purpose of this research study is to see if ganetespib could be a safe and effective treatment for advanced breast cancer.

Study Details

Inclusion Criteria

  • Invasive breast cancer
  • Stage IV disease
  • Adequate hamatological, hepatic, and renal functions

Exclusion Criteria

  • A new diagnosed subjects with HER2+ disease
  • Presence of active or untreated CNS metastases
  • Bone as the only site of metastatic disease from breast cancer

Study Requirements

Participants will be randomized to two groups. Group A includes HER2+ breast cancer participants and Group B includes triple negative breast cancer participants. Both groups will receive Ganetespib monotherapy. Participants will have medical exams, blood draws, PET/CT, MRI and other scans necessary for this study.

Nurse navigators for cancer patients at Tufts Medical Center.

Are you interested in learning more about this clinical trial?

Send us a message and we'll get back to you with more information.

Request information